Clinical trials: Keratitis
Corneal Ulcer, Eye Infections, Bacterial
Steroids for Corneal Ulcers Trial
The purpose of this study is to determine whether adding topical steroids improves the outcomes of bacterial corneal ulcers, especially visual acuity.
- Trial name
- SCUT (NCT00324168)
- Testing
- Antibiotics, Topical corticosteroid
- Where
- 5 sites in United States, India
- Volunteers
- 500 people
- Sponsor
- Thomas M. Lietman
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Dry Eye Disease With Severe Keratitis
3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED)…
- Trial name
- NCT04144413
- Testing
- Open-label Ikervis, Masked Ikervis, Vehicle Comparator: Masked Vehicle
- Where
- 45 sites in Czechia, France and 5 more
- Volunteers
- 350 people
- Sponsor
- Santen SAS
Dry Eye Syndromes
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye…
- Trial name
- NCT02313454
- Testing
- Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Allergan
Dry Eye
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
The study was planned to be conducted in 2 parts: Part 1 to determine the efficacy and safety of ECF843 vs vehicle, followed by Part 2 with additional exploratory assessments of ECF843 vs Vehicle.
- Trial name
- NCT04391894
- Testing
- ECF843, ECF843 vehicle
- Where
- 52 sites in United States
- Volunteers
- 718 people
- Sponsor
- Novartis Pharmaceuticals
Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Topical rVA576 for treatment of atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC),and severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC)): a randomised placebo-controlled double masked parallel…
- Conditions
- Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal, Conjunctivitis, Allergic
- Trial name
- NCT04037891
- Testing
- rVA576
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 12 people
- Sponsor
- AKARI Therapeutics
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
- Trial name
- NCT02526290
- Testing
- Intranasal Lacrimal Neurostimulator (Oculeve)
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Oculeve, Inc.
Neurotrophic Keratitis
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Primary Objective To evaluate the long-term safety and efficacy (healing) of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 neurotrophic keratitis (NK) patients who enrolled in the DEFENDO study.
- Trial name
- NCT05552261
- Testing
- Cenegemin in the DEFENDO Study
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dompé Farmaceutici S.p.A
Fungal Keratitis
Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
We evaluated whether voriconazole is a superior treatment to natamycin for filamentous fungal keratitis in a randomized, masked, controlled trial.
- Trial name
- MUTT_TE (NCT00557362)
- Testing
- Natamycin 5%, Voriconazole, Corneal de-epithelialization
- Where
- 2 sites in India
- Volunteers
- 120 people
- Sponsor
- University of California, San Francisco
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.